StockIQ.techKymera Therapeutics, Inc. (KYMR) Stock Analysis
Free AI-powered analysis and research for Kymera Therapeutics, Inc. stock
Sector: Healthcare
KYMR snapshot
Data as of 3 Nov 2026 close. Updated daily.
Kymera Therapeutics, Inc. scores 74/100 on StockIQ's model, which reads as positive signals overall. The price is above its 200-day average and at 94% of its 52-week range, up 116.2% over the past year. Latest reported figures show a profit margin of 0.0% and return on equity of -27.3%.
What is driving the score
- Uptrend: +3
- MACD Bullish: +8
- Weak Profit Margin (0.0%): -8
- Low Debt (0.05 D/E): +8
- Strong Liquidity (11.13 Current Ratio): +8
- Negative ROE (-27.3%): -10
- High P/B (6.69): -5
- Strong Long-term Uptrend: +8
- Very Strong Rise (+116.2% over 1 year): +12
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full KYMR report
Kymera Therapeutics, Inc. (KYMR) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze KYMR Now →📰 Latest Update
Kymera Therapeutics, Inc. Q3 2026 Earnings Call Summary
Thu, October 29, 2026 at 10:53 PM UTC 4 min read
Kymera Therapeutics, Inc. reported its Q3 2026 earnings, highlighting a significant increase in revenue driven by advancements in its drug development pipeline. The company's progress in clinical trials for its targeted protein degradation therapies positions it favorably in the competitive biotech landscape. For investors, this strong performance and promising pipeline suggest potential for future growth and increased shareholder value.